In breast cancer, imatinib inhibits the acetyltransferase activity of p300, leading to decreased levels of H3K18Ac and H3K27Ac, thereby downregulating Hes1 expression and inhibiting EMT (127). The gene discussed is HES1; the disease is breast carcinoma.